TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Return
18.15%
This Quarter Return
-1.41%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.59B
AUM Growth
-$205M
(-7.3%)
Cap. Flow
-$97.3M
Cap. Flow
% of AUM
-3.75%
Top 10 Holdings %
Top 10 Hldgs %
43.13%
Holding
169
New
17
Increased
28
Reduced
45
Closed
8
Top Buys
| 1 |
Amgen
AMGN
|
$42.1M |
| 2 |
AbbVie
ABBV
|
$23.4M |
| 3 |
Bristol-Myers Squibb
BMY
|
$21.4M |
| 4 |
CELG
Celgene Corp
CELG
|
$13.2M |
| 5 |
SAGE
Sage Therapeutics
SAGE
|
$11.2M |
Top Sells
| 1 |
Abbott
ABT
|
$25.8M |
| 2 |
Jazz Pharmaceuticals
JAZZ
|
$23.6M |
| 3 |
AGN
Allergan plc
AGN
|
$21.4M |
| 4 |
Gilead Sciences
GILD
|
$20.1M |
| 5 |
Neurocrine Biosciences
NBIX
|
$18.4M |
Sector Composition
| 1 | Healthcare | 92.75% |
| 2 | Real Estate | 2.87% |
| 3 | Financials | 0.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Thermo Fisher Scientific
TMO
$181B
| $26.2M | 1.01% |
137,968
-81,104
| -37% | -$15.4M |
|
|
27
Neurocrine Biosciences
NBIX
$13.6B
| $25.2M | 0.97% |
325,067
-237,400
| -42% | -$18.4M |
|
28
Centene
CNC
$14.2B
| $23.2M | 0.9% |
460,316
| – | – |
|
|
29
Bristol-Myers Squibb
BMY
$96.1B
| $21.4M | 0.83% |
+349,121
| New | +$21.4M |
|
30
Idexx Laboratories
IDXX
$50.5B
| $20.7M | 0.8% |
132,352
| – | – |
|
31
Cigna
CI
$80.8B
| $20.3M | 0.78% |
100,002
| – | – |
|
32
McKesson
MCK
$86.3B
| $19.3M | 0.75% |
123,950
-18,850
| -13% | -$2.94M |
|
33
SPDR S&P Biotech ETF
XBI
$5.26B
| $19.2M | 0.74% |
226,460
| – | – |
|
34
Sarepta Therapeutics
SRPT
$1.92B
| $18.6M | 0.72% |
334,400
-202,200
| -38% | -$11.3M |
|
35
Omega Healthcare
OHI
$12.6B
| $16M | 0.62% |
579,785
+121,169
| +26% | +$3.34M |
|
36
Cencora
COR
$57.7B
| $15.4M | 0.59% |
167,307
-120,880
| -42% | -$11.1M |
|
37
AstraZeneca
AZN
$254B
| $15.4M | 0.59% |
442,600
| – | – |
|
|
PVLA
38
Palvella Therapeutics, Inc. Common Stock
PVLA
$591M
| $14.8M | 0.57% |
24,530
-10,940
| -31% | -$6.61M |
|
39
Alnylam Pharmaceuticals
ALNY
$60B
| $14.6M | 0.56% |
114,966
| – | – |
|
40
Novo Nordisk
NVO
$249B
| $14.6M | 0.56% |
543,600
+396,400
| +269% | +$10.6M |
|
41
Sabra Healthcare REIT
SBRA
$4.57B
| $13.6M | 0.52% |
724,606
+173,616
| +32% | +$3.26M |
|
|
NVRO
42
DELISTED
NEVRO CORP.
NVRO
| $13.4M | 0.52% |
194,621
| – | – |
|
|
43
Jazz Pharmaceuticals
JAZZ
$7.92B
| $13.3M | 0.51% |
98,421
-175,495
| -64% | -$23.6M |
|
|
DPLO
44
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
| $12.9M | 0.5% |
640,492
+178,780
| +39% | +$3.59M |
|
45
GSK
GSK
$79.4B
| $12.7M | 0.49% |
287,200
| – | – |
|
|
DHC
46
Diversified Healthcare Trust
DHC
$915M
| $12.4M | 0.48% |
646,554
| – | – |
|
|
XLRN
47
DELISTED
Acceleron Pharma Inc.
XLRN
| $12M | 0.46% |
283,383
+223,729
| +375% | +$9.5M |
|
|
WELL.PRI
48
DELISTED
Welltower Inc.
WELL.PRI
| $12M | 0.46% |
200,000
| – | – |
|
|
SGEN
49
DELISTED
Seagen Inc. Common Stock
SGEN
| $12M | 0.46% |
223,700
| – | – |
|
50
Medical Properties Trust
MPW
$2.64B
| $11.8M | 0.46% |
858,586
-149,131
| -15% | -$2.05M |
|